First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback